Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial.
Saved in:
| Title: | Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial. |
|---|---|
| Authors: | Blasiak A; The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore. agatablasiak@gmail.com.; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore. agatablasiak@gmail.com.; Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, Singapore. agatablasiak@gmail.com.; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. agatablasiak@gmail.com., Truong ATL; The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore.; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore.; Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, Singapore., Foo N; The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore.; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore.; Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, Singapore., Tan LWJ; The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore.; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore.; Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, Singapore., Kumar KS; The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore.; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore., Tan SB; The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore.; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore., Teo CB; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Tan BKJ; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Tadeo X; The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore.; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore., Tan HL; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore., Chee CE; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore., Yong WP; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore.; Singapore Gastric Cancer Consortium, Department of Medicine, National University of Singapore, Singapore, Singapore., Ho D; The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore. biedh@nus.edu.sg.; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore. biedh@nus.edu.sg.; Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, Singapore. biedh@nus.edu.sg.; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. biedh@nus.edu.sg.; Singapore Gastric Cancer Consortium, Department of Medicine, National University of Singapore, Singapore, Singapore. biedh@nus.edu.sg.; The Bia-Echo Asia Centre for Reproductive Longevity and Equality (ACRLE), National University of Singapore, Singapore, Singapore. biedh@nus.edu.sg., Sundar R; The N.1 Institute for Health (N.1), National University of Singapore, Singapore, Singapore. raghav.sundar@yale.edu.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. raghav.sundar@yale.edu.; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore. raghav.sundar@yale.edu.; Singapore Gastric Cancer Consortium, Department of Medicine, National University of Singapore, Singapore, Singapore. raghav.sundar@yale.edu. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2025 Feb 21; Vol. 9 (1), pp. 49. Date of Electronic Publication: 2025 Feb 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-025-00835-7 |
